Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
REDWOOD CITY, Calif., Sept. 20, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective September 19, 2019, the compensation committee of the company’s...
-
REDWOOD CITY, Calif., Aug. 22, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective August 21, 2019, the compensation committee of the company’s board of...
-
REDWOOD CITY, Calif., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that senior management will present at two upcoming investor healthcare conferences....
-
– Company is Profitable and Cash flow Positive from Operations for Second Quarter – – UDENYCA® is the Market Leading Pegfilgrastim Biosimilar with Approximately 13% Market Share – ...
-
REDWOOD CITY, Calif., July 29, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced that the United States Court of Appeals for the Federal...
-
REDWOOD CITY, Calif., July 19, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective July 18, 2019, the compensation committee of the company’s board of...
-
REDWOOD CITY, Calif., July 08, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced that UDENYCA® preliminary unaudited net sales for the...
-
REDWOOD CITY, Calif., July 08, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced that its second quarter 2019 financial results will be...
-
REDWOOD CITY, Calif., July 01, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or “the Company,” Nasdaq: CHRS), is pleased to announce that it has produced over 400,000 UDENYCA®...
-
REDWOOD CITY, Calif., June 21, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective June 20, 2019, the compensation committee of the company’s board of...